Description: Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.
Home Page: www.decibeltx.com
DBTX Technical Analysis
1325 Boylston Street
Boston,
MA
02215
United States
Phone:
617 370 8701
Officers
| Name | Title |
|---|---|
| Dr. Laurence E. Reid Ph.D. | Pres, CEO & Director |
| Mr. John J. Lee | Chief Devel. Officer |
| Mr. M. Charles Liberman | Co-Founder & Member of Scientific Advisory Board |
| Dr. Gabriel Corfas | Co-Founder & Member of Scientific Advisory Board |
| Dr. Ulrich Müller | Co-Founder & Member of Scientific Advisory Board |
| Dr. Albert S. B. Edge | Co-Founder & Member of Scientific Advisory Board |
| Mr. James B. Murphy | Interim CFO, Principal Financial Officer & Principal Accounting Officer |
| Ms. Elaine Cope | VP of Operations |
| Ms. Anna Trask M.A. | Exec. VP & Chief People Officer |
| Mr. Joe Burns Ph.D. | Sr. VP of Discovery |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6679 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 62 |